Trial reportThe Journal of pediatrics2016
Caffeine for the Treatment of Apnea in Bronchiolitis: A Randomized Trial.
Trial report in The Journal of pediatrics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01435486 (Caffeine Citrate for the Treatment of Apnea Associated With Bronchiolitis in Young Infants), which is not on this map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Caffeine Citrate for the Treatment of Apnea Associated With Bronchiolitis in Young Infants: A Randomized, Double Blind, Controlled Trial (RCT)
Who cites it
5 citing papers in PubMed, 20 citations in OpenAlex.
- Caffeine citrate increases ciliary beat frequency in human respiratory epithelial cells.Molecular and cellular pediatrics · 2026Article
- Successful Use of Caffeine Citrate for Neonate With Bronchiolitis-Related Apnea: Case Report and Clinical Insights.Clinical case reports · 2025Article
- Caffeine-clarithromycin coadministration and hyperlactatemia in a young infant: a case report.Critical care science · 2025Article
- Non-pulmonary manifestations of respiratory syncytial virus infection.Journal of thoracic disease · 2018Article
- Caffeine to prevent respiratory failure and improve outcome in infant pertussis.BMJ case reports · 2018Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on byReply.2017
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the efficacy and safety of caffeine citrate in the treatment of apnea in bronchiolitis. STUDY
designEligible infants aged ≤4 months presenting to the main pediatric emergency service with apnea associated bronchiolitis were stratified by gestational age (<34 weeks or longer) and randomized to receive a single dose of intravenous 25 mg/kg caffeine citrate or saline placebo. The primary efficacy outcome was a 24-hour apnea-free period beginning after completion of the blinded study drug infusion. Secondary outcomes were frequency of apnea by 24, 48, and 72 hours after study medication, need for noninvasive/invasive ventilation, and length of stay in the hospital's pediatric intensive care/step-down unit.
resultsA total of 90 infants diagnosed with viral bronchiolitis associated with apnea (median age, 38 days) were enrolled. The rate of respiratory virus panel positivity was similar in the 2 groups (78% for the placebo group vs 84% for the caffeine group). The geometric mean duration to a 24-hour apnea-free period was 28.1 hours (95% CI, 25.6-32.3 hours) for the caffeine group and 29.1 hours (95% CI, 25.7-32.9 hours) for the placebo group (P = .88; OR, 0.99; 95% CI, 0.83-1.17). The frequency of apnea at 24 hours, 24-48 hours, and 48-72 hours after enrollment and the need for noninvasive and invasive ventilation were similar in the 2 groups. No safety issues were reported.
conclusionsA single dose of caffeine citrate did not significantly reduce apnea episodes associated with bronchiolitis.
trial registrationClinicaltrials.gov: NCT01435486.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.